Compare IE & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IE | STOK |
|---|---|---|
| Founded | 2020 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | 2022 | 2019 |
| Metric | IE | STOK |
|---|---|---|
| Price | $12.79 | $30.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | $18.17 | ★ $39.20 |
| AVG Volume (30 Days) | ★ 1.8M | 417.6K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 92.73 |
| EPS | ★ N/A | N/A |
| Revenue | $3,244,000.00 | ★ $184,420,000.00 |
| Revenue This Year | $44.79 | N/A |
| Revenue Next Year | $16.22 | $77.49 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 11.82 | ★ 404.50 |
| 52 Week Low | $6.53 | $9.09 |
| 52 Week High | $21.55 | $40.22 |
| Indicator | IE | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 43.78 | 31.93 |
| Support Level | $12.11 | $25.21 |
| Resistance Level | $13.63 | $35.11 |
| Average True Range (ATR) | 0.86 | 1.56 |
| MACD | -0.01 | -0.32 |
| Stochastic Oscillator | 17.69 | 6.05 |
Ivanhoe Electric Inc is a United States-based d minerals exploration company with a focus on developing mines from mineral deposits principally located in the United States. The company has four business segments; Santa Cruz Project; critical metals; data processing services; and energy storage. It derives a majority of its revenue from Canada. The Santa Cruz Project and critical metals segments are focused on mineral project exploration and development. The data processing segment provides data analytics, geophysical modeling, and artificial intelligence services for the mineral, oil & gas, and water exploration industries. The energy storage segment develops, manufactures, and installs vanadium flow batteries for grid-scale energy storage.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.